Influenza drug oseltamivir has made vast amounts of pounds for Roche, but why won’t the organization give patients and physicians usage of the total data that are clinical? Included in the BMJ’s open information campaign, we this week introduce a brand new website committed to your cause. David Payne reports

This week the BMJ, included in its ongoing data that are open, has launched a separate website aimed at persuading Roche to provide physicians and clients usage of the total information on oseltamivir (Tamiflu). (tovább…)